CORD-19:867ebb2be2d466bcb35e5a7319708eaff39c4799 / 2027-2493 JSONTXT

Annnotations TAB JSON ListView MergeView

    CORD-19_Custom_license_subset

    {"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T18","span":{"begin":0,"end":466},"obj":"Sentence"}],"text":"• Ceftriaxone; community acquired pneumonia (29%), infective exacerbation of chronic obstructive pulmonary disease (11%) and urinary tract infection (11%) • Amoxycillin-clavulanic acid; community acquired pneumonia (31%), infective exacerbation of chronic obstructive pulmonary disease (20%) and urinary tract infection (10%) • Piperacillin-tazobactam; community acquired pneumonia (14%), hospital acquired pneumonia (10%) and cellulitis/ erysipelas (7%) Conclusion:"}

    CORD-19-Sentences

    {"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T18","span":{"begin":0,"end":466},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"• Ceftriaxone; community acquired pneumonia (29%), infective exacerbation of chronic obstructive pulmonary disease (11%) and urinary tract infection (11%) • Amoxycillin-clavulanic acid; community acquired pneumonia (31%), infective exacerbation of chronic obstructive pulmonary disease (20%) and urinary tract infection (10%) • Piperacillin-tazobactam; community acquired pneumonia (14%), hospital acquired pneumonia (10%) and cellulitis/ erysipelas (7%) Conclusion:"}

    CORD-19-PD-HP

    {"project":"CORD-19-PD-HP","denotations":[{"id":"T2","span":{"begin":34,"end":43},"obj":"Phenotype"},{"id":"T3","span":{"begin":77,"end":114},"obj":"Phenotype"},{"id":"T4","span":{"begin":125,"end":148},"obj":"Phenotype"},{"id":"T5","span":{"begin":205,"end":214},"obj":"Phenotype"},{"id":"T6","span":{"begin":248,"end":285},"obj":"Phenotype"},{"id":"T7","span":{"begin":296,"end":319},"obj":"Phenotype"},{"id":"T8","span":{"begin":372,"end":381},"obj":"Phenotype"},{"id":"T9","span":{"begin":407,"end":416},"obj":"Phenotype"},{"id":"T10","span":{"begin":427,"end":437},"obj":"Phenotype"},{"id":"T11","span":{"begin":439,"end":449},"obj":"Phenotype"}],"attributes":[{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0006510"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0000010"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0006510"},{"id":"A7","pred":"hp_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/HP_0000010"},{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0100658"},{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0001055"}],"text":"• Ceftriaxone; community acquired pneumonia (29%), infective exacerbation of chronic obstructive pulmonary disease (11%) and urinary tract infection (11%) • Amoxycillin-clavulanic acid; community acquired pneumonia (31%), infective exacerbation of chronic obstructive pulmonary disease (20%) and urinary tract infection (10%) • Piperacillin-tazobactam; community acquired pneumonia (14%), hospital acquired pneumonia (10%) and cellulitis/ erysipelas (7%) Conclusion:"}

    CORD-19-PD-MONDO

    {"project":"CORD-19-PD-MONDO","denotations":[{"id":"T3","span":{"begin":34,"end":43},"obj":"Disease"},{"id":"T4","span":{"begin":77,"end":114},"obj":"Disease"},{"id":"T5","span":{"begin":97,"end":114},"obj":"Disease"},{"id":"T6","span":{"begin":125,"end":148},"obj":"Disease"},{"id":"T8","span":{"begin":139,"end":148},"obj":"Disease"},{"id":"T9","span":{"begin":205,"end":214},"obj":"Disease"},{"id":"T10","span":{"begin":248,"end":285},"obj":"Disease"},{"id":"T11","span":{"begin":268,"end":285},"obj":"Disease"},{"id":"T12","span":{"begin":296,"end":319},"obj":"Disease"},{"id":"T14","span":{"begin":310,"end":319},"obj":"Disease"},{"id":"T15","span":{"begin":372,"end":381},"obj":"Disease"},{"id":"T16","span":{"begin":407,"end":416},"obj":"Disease"},{"id":"T17","span":{"begin":427,"end":437},"obj":"Disease"},{"id":"T18","span":{"begin":439,"end":449},"obj":"Disease"},{"id":"T83355","span":{"begin":34,"end":43},"obj":"Disease"},{"id":"T52401","span":{"begin":77,"end":114},"obj":"Disease"},{"id":"T57746","span":{"begin":97,"end":114},"obj":"Disease"},{"id":"T88992","span":{"begin":125,"end":148},"obj":"Disease"},{"id":"T40839","span":{"begin":139,"end":148},"obj":"Disease"},{"id":"T49514","span":{"begin":205,"end":214},"obj":"Disease"},{"id":"T11268","span":{"begin":248,"end":285},"obj":"Disease"},{"id":"T76901","span":{"begin":268,"end":285},"obj":"Disease"},{"id":"T57296","span":{"begin":296,"end":319},"obj":"Disease"},{"id":"T5784","span":{"begin":310,"end":319},"obj":"Disease"},{"id":"T67885","span":{"begin":372,"end":381},"obj":"Disease"},{"id":"T84347","span":{"begin":407,"end":416},"obj":"Disease"},{"id":"T31594","span":{"begin":427,"end":437},"obj":"Disease"},{"id":"T18723","span":{"begin":439,"end":449},"obj":"Disease"}],"attributes":[{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0005002"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0001650"},{"id":"A7","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005247"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005002"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0001650"},{"id":"A13","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0005247"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0005230"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0001266"},{"id":"A80883","pred":"mondo_id","subj":"T83355","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A40716","pred":"mondo_id","subj":"T52401","obj":"http://purl.obolibrary.org/obo/MONDO_0005002"},{"id":"A25089","pred":"mondo_id","subj":"T57746","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"},{"id":"A29123","pred":"mondo_id","subj":"T88992","obj":"http://purl.obolibrary.org/obo/MONDO_0001650"},{"id":"A61065","pred":"mondo_id","subj":"T88992","obj":"http://purl.obolibrary.org/obo/MONDO_0005247"},{"id":"A81876","pred":"mondo_id","subj":"T40839","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A6257","pred":"mondo_id","subj":"T49514","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A7003","pred":"mondo_id","subj":"T11268","obj":"http://purl.obolibrary.org/obo/MONDO_0005002"},{"id":"A80543","pred":"mondo_id","subj":"T76901","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"},{"id":"A56252","pred":"mondo_id","subj":"T57296","obj":"http://purl.obolibrary.org/obo/MONDO_0001650"},{"id":"A86905","pred":"mondo_id","subj":"T57296","obj":"http://purl.obolibrary.org/obo/MONDO_0005247"},{"id":"A88793","pred":"mondo_id","subj":"T5784","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A19655","pred":"mondo_id","subj":"T67885","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A58458","pred":"mondo_id","subj":"T84347","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A7917","pred":"mondo_id","subj":"T31594","obj":"http://purl.obolibrary.org/obo/MONDO_0005230"},{"id":"A39496","pred":"mondo_id","subj":"T18723","obj":"http://purl.obolibrary.org/obo/MONDO_0001266"}],"text":"• Ceftriaxone; community acquired pneumonia (29%), infective exacerbation of chronic obstructive pulmonary disease (11%) and urinary tract infection (11%) • Amoxycillin-clavulanic acid; community acquired pneumonia (31%), infective exacerbation of chronic obstructive pulmonary disease (20%) and urinary tract infection (10%) • Piperacillin-tazobactam; community acquired pneumonia (14%), hospital acquired pneumonia (10%) and cellulitis/ erysipelas (7%) Conclusion:"}